O2TODAY and SINTX Technologies Enter Commercialization Agreement to Fight COVID-19
Retrieved on:
Thursday, February 25, 2021
Manufacturing, Other Health, Technology, Women, Seniors, Parenting, MEN, Other Manufacturing, Other Technology, Textiles, Science, Other Science, Consumer, Research, Health, Medical Supplies, Materials, Nitrides, Silicon nitride, Light-emitting diode, Matter, Goods economics), O2TODAY, SINTX Technologies, Inc.
Since the outbreak of COVID-19, SINTX Technologies has been testing the antiviral properties of silicon nitride for use in antipathogenic applications.
Key Points:
- Since the outbreak of COVID-19, SINTX Technologies has been testing the antiviral properties of silicon nitride for use in antipathogenic applications.
- O2TODAY and SINTX entered a collaboration during 2020 shortly after the COVID-19 pandemic was underway.
- The agreement includes a license fee, a commercial agreement on silicon nitride sales, and royalties based upon product sales of the masks and filters.
- We are thrilled to enter this agreement with SINTX Technologies, a company that has a remarkable history of conducting the science and developing products based on silicon nitride and its various formulations, said Bruce Lorange, CEO of O2TODAY.